Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain's immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company's immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer's disease. This scientific approach is also the basis for the Company's immuno-oncology programs.
Company profile
Ticker
ALEC
Exchange
Website
CEO
Arnon Rosenthal
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
Former names
Alector LLC
SEC CIK
Corporate docs
Subsidiaries
Alector LLC ...
IRS number
462702363
ALEC stock data
Analyst ratings and price targets
Current price
Average target
$14.00
Low target
$11.00
High target
$17.00
Morgan Stanley
Maintains
$11.00
Citigroup
Maintains
$17.00
Latest filings (excl ownership)
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Alector Reports Third Quarter 2022 Financial Results and Provides Business Update
8 Nov 22
8-K
Departure of Directors or Certain Officers
5 Oct 22
S-8
Registration of securities for employees
23 Sep 22
8-K
Departure of Directors or Certain Officers
23 Sep 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Alector Reports Second Quarter 2022 Financial Results and Provides Business Update
4 Aug 22
8-K
Other Events
7 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 22
DEFR14A
Revised proxy
27 May 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 185.70 mm | 185.70 mm | 185.70 mm | 185.70 mm | 185.70 mm | 185.70 mm |
| Cash burn (monthly) | (no burn) | 27.69 mm | 15.92 mm | 11.51 mm | 16.35 mm | 1.72 mm |
| Cash used (since last report) | n/a | 111.42 mm | 64.04 mm | 46.31 mm | 65.79 mm | 6.93 mm |
| Cash remaining | n/a | 74.29 mm | 121.67 mm | 139.39 mm | 119.92 mm | 178.77 mm |
| Runway (months of cash) | n/a | 2.7 | 7.6 | 12.1 | 7.3 | 103.8 |
Institutional ownership, Q3 2022
82.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 165 |
| Opened positions | 29 |
| Closed positions | 16 |
| Increased positions | 58 |
| Reduced positions | 43 |
| 13F shares | Current |
|---|---|
| Total value | 765.68 mm |
| Total shares | 68.28 mm |
| Total puts | 61.00 k |
| Total calls | 387.40 k |
| Total put/call ratio | 0.2 |
| Largest owners | Shares | Value |
|---|---|---|
| Polaris Venture Partners VI | 12.35 mm | $255.11 mm |
| BLK Blackrock | 6.00 mm | $56.79 mm |
| Vanguard | 5.75 mm | $54.43 mm |
| FHI Federated Hermes | 5.66 mm | $53.51 mm |
| FMR | 4.72 mm | $44.69 mm |
| EcoR1 Capital | 4.06 mm | $38.38 mm |
| MRK Merck & Co | 3.55 mm | $0.00 |
| JPM JPMorgan Chase & Co. | 2.38 mm | $22.55 mm |
| Flynn James E | 1.96 mm | $33.62 mm |
| T. Rowe Price | 1.74 mm | $16.49 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Nov 22 | Mcguire Terrance | Common Stock | Other | Acquire J | Yes | No | 0 | 13,133 | 0.00 | 26,266 |
| 16 Nov 22 | Mcguire Terrance | Common Stock | Other | Dispose J | Yes | No | 0 | 98,533 | 0.00 | 0 |
| 16 Nov 22 | Mcguire Terrance | Common Stock | Other | Acquire J | Yes | No | 0 | 98,533 | 0.00 | 98,553 |
| 16 Nov 22 | Mcguire Terrance | Common Stock | Other | Acquire J | No | No | 0 | 6,429 | 0.00 | 22,317 |
| 16 Nov 22 | Mcguire Terrance | Common Stock | Other | Dispose J | Yes | No | 0 | 500,000 | 0.00 | 11,853,817 |
| 16 Nov 22 | Polaris Venture Management Co. VI, L.L.C. | Common Stock | Other | Dispose J | No | No | 0 | 98,533 | 0.00 | 0 |
| 16 Nov 22 | Polaris Venture Management Co. VI, L.L.C. | Common Stock | Other | Acquire J | No | No | 0 | 98,533 | 0.00 | 98,533 |
| 16 Nov 22 | Polaris Venture Management Co. VI, L.L.C. | Common Stock | Other | Dispose J | Yes | No | 0 | 500,000 | 0.00 | 11,853,817 |
| 1 Oct 22 | Arnon Rosenthal | Common Stock | Grant | Acquire A | No | No | 0 | 179,169 | 0.00 | 1,634,395 |
| 1 Oct 22 | Arnon Rosenthal | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 9.46 | 119,446 | 1.13 mm | 119,446 |
News
Morgan Stanley Maintains Equal-Weight on Alector, Lowers Price Target to $11
24 Jan 23
Alector Presents Results From First-in-Human Phase 1 Study Of AL101 For The Treatment Of Neurodegenerative Diseases
29 Nov 22
Citigroup Maintains Buy on Alector, Lowers Price Target to $17
10 Nov 22
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
10 Nov 22
Alector Q3 EPS $(0.56) Down From $1.49 YoY, Sales $14.85M Down From $182.41M YoY
8 Nov 22